Resistance Mechanisms in ROS1-Positive Lung Cancer: New Insight into a Rare but Clinically Important Entity

Clin Chem. 2024 Apr 3;70(4):571-573. doi: 10.1093/clinchem/hvae021.

Authors

Mitchell S von Itzstein^{1

2}, David E Gerber^{1

2

3}

Affiliations

¹ Department of Internal Medicine (Division of Hematology-Oncology), University of Texas Southwestern Medical Center, Dallas, TX, United States.
² Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, United States.
³ Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, United States.

PMID: 38416703
DOI: 10.1093/clinchem/hvae021

No abstract available

Publication types

Editorial
Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung*
Humans
Lung Neoplasms* / diagnosis
Protein-Tyrosine Kinases / antagonists & inhibitors
Proto-Oncogene Proteins / antagonists & inhibitors
Tyrosine Kinase Inhibitors

Substances

Protein-Tyrosine Kinases
Tyrosine Kinase Inhibitors
Proto-Oncogene Proteins
ROS1 protein, human